enGene Therapeutics Inc. Common Stock (ENGN)
Stock · NASDAQ · Health Care
$1.83as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$1.73
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was former…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 81
- Website
- engene.com
Fundamentals
- 1-day range
- $1.79$1.84
- Market cap
- $120.58M
- P/E (trailing)
- —
- P/E (forward)
- -1.28
- EPS (trailing)
- $-2.18
- Dividend yield
- —
- Beta
- -0.29
- Avg. volume
- 1.28M
52-week range
$1.4$12.25
Next earnings: September 14, 2026 · EPS estimate $-0.43confirmed
Forecasts
7 analyst ratings
Buy 56%
Hold 39%
Sell 6%
1-year price forecast
High
$5
+173.2%
Median
$4
+118.6%
Low
$2
+9.3%
enGene Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ENGNenGene Therapeutics Inc. Common Stock$1.83▼ 4.19%Market cap $120.58MP/E —$1.4$12.25
- BDTXBlack Diamond Therapeutics Inc. Common Stock$2.23▼ 1.76%Market cap $110.02MP/E —$1.6$4.94
- PTHSPelthos Therapeutics Inc. Common Stock$24.46▼ 2.16%Market cap $102.36MP/E —$18.19$37.5
- CGTXCognition Therapeutics Inc. Common Stock$1.03▼ 3.30%Market cap $101.13MP/E —$0.5501$2.79
- KLRSKalaris Therapeutics Inc. Common Stock$4.03▼ 1.71%Market cap $99.69MP/E —$3.03$11.88
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.94▼ 6.07%Market cap $156.77MP/E —$1.23$3.15
- TNYATenaya Therapeutics Inc. Common Stock$0.691▼ 0.58%Market cap $157.50MP/E —$0.532$2.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.83 | ▼ 4.19% | $1.4$12.25 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $2.23 | ▼ 1.76% | $1.6$4.94 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $24.46 | ▼ 2.16% | $18.19$37.5 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $1.03 | ▼ 3.30% | $0.5501$2.79 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $4.03 | ▼ 1.71% | $3.03$11.88 |
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.94 | ▼ 6.07% | $1.23$3.15 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.691 | ▼ 0.58% | $0.532$2.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer TranscriptSeekingAlpha · 8/11/2026
- enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - SlideshowSeekingAlpha · 8/11/2026
- enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026Yahoo · 8/4/2026
Insider Activity
Insider Actions →Acquired
186.0K
Disposed
0
- Heffernan Michael Thomas · June 16, 2026 · Grant31.0K
- BRUNK GERALD A · June 16, 2026 · Grant31.0K
- Astley-Sparke Philip · June 16, 2026 · Grant31.0K
- Glickman Richard M · June 16, 2026 · Grant31.0K
- Paul J. Hastings · June 16, 2026 · Grant31.0K
- Lota S. Zoth · June 16, 2026 · Grant31.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 344.0K
- Total value held
- $2.34M
- Institutional holders
- 2
Top holders this quarter
- Unknown343.9K
- Unknown28
See the full, filterable feed with live charts on the MarketWall dashboard.